BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. 2004

A Villar, and S Aronis, and M Morfini, and E Santagostino, and G Auerswald, and H F Thomsen, and E Erhardtsen, and P L F Giangrande
Hospital Universitario La Paz de Madrid, Madrid, Spain.

To establish the pharmacokinetic profile of activated recombinant coagulation factor VII (rFVIIa; NovoSeven in children with haemophilia A, and to compare it with the pharmacokinetic profile in adults with haemophilia A. Twelve children (2-12 years) received one single dose of rFVIIa 90 and 180 micrograms kg(-1) in randomized order separated by a washout period of 48 h to 1 month. Six adults (18-55 years) received a single dose of rFVIIa 90 micrograms kg(-1). The pharmacokinetic analyses were based on a non-compartmental method. In children, the plasma level of FVII increased proportionally with the dose. The total body clearance normalized for body weight was significantly faster in children than in adults (FVII:C, 58 vs. 39 mL kg(-1) h(-1) and FVIIa, 78 vs. 53 mL kg(-1) h(-1), P < 0.05). A trend towards a larger volume of distribution at steady-state in children than in adults was observed (P > 0.05). Dose proportionality was established for plasma concentrations of FVII in children with haemophilia A at the dose levels investigated (90 and 180 micrograms kg(-1) rFVIIa). Following administration of rFVIIa 90 micrograms kg(-1), significantly faster clearance was observed in children compared with adults, suggesting that higher doses of rFVIIa may be needed to achieve the same plasma levels as in adults.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D010949 Plasma The residual portion of BLOOD that is left after removal of BLOOD CELLS by CENTRIFUGATION without prior BLOOD COAGULATION. Blood Plasma,Fresh Frozen Plasma,Blood Plasmas,Fresh Frozen Plasmas,Frozen Plasma, Fresh,Frozen Plasmas, Fresh,Plasma, Blood,Plasma, Fresh Frozen,Plasmas,Plasmas, Blood,Plasmas, Fresh Frozen
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005167 Factor VII Heat- and storage-stable plasma protein that is activated by tissue thromboplastin to form factor VIIa in the extrinsic pathway of blood coagulation. The activated form then catalyzes the activation of factor X to factor Xa. Coagulation Factor VII,Proconvertin,Stable Factor,Blood Coagulation Factor VII,Factor 7,Factor Seven,Factor VII, Coagulation
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006467 Hemophilia A The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage. Factor VIII Deficiency,Hemophilia,Autosomal Hemophilia A,Classic Hemophilia,Deficiency, Factor VIII,Factor 8 Deficiency, Congenital,Factor VIII Deficiency, Congenital,Haemophilia,Hemophilia A, Congenital,Hemophilia, Classic,As, Autosomal Hemophilia,Autosomal Hemophilia As,Classic Hemophilias,Congenital Hemophilia A,Congenital Hemophilia As,Hemophilia A, Autosomal,Hemophilia As,Hemophilia As, Autosomal,Hemophilia As, Congenital,Hemophilias, Classic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015942 Factor VIIa Activated form of factor VII. Factor VIIa activates factor X in the extrinsic pathway of blood coagulation. Coagulation Factor VIIa,Factor VII, Activated,Blood Coagulation Factor VII, Activated,Factor 7A,Factor Seven A,Activated Factor VII,Factor VIIa, Coagulation

Related Publications

A Villar, and S Aronis, and M Morfini, and E Santagostino, and G Auerswald, and H F Thomsen, and E Erhardtsen, and P L F Giangrande
[Using recombinant activated coagulation factor VII (NovoSeven) in obstetrics].
January 2003, Akusherstvo i ginekologiia,
A Villar, and S Aronis, and M Morfini, and E Santagostino, and G Auerswald, and H F Thomsen, and E Erhardtsen, and P L F Giangrande
Recombinant activated factor VII (rFVIIa, NovoSeven).
August 2005, The Journal of the Association of Physicians of India,
A Villar, and S Aronis, and M Morfini, and E Santagostino, and G Auerswald, and H F Thomsen, and E Erhardtsen, and P L F Giangrande
Use of activated recombinant Factor VII (NovoSeven) during neurosurgery.
October 2003, Journal of neurosurgical anesthesiology,
A Villar, and S Aronis, and M Morfini, and E Santagostino, and G Auerswald, and H F Thomsen, and E Erhardtsen, and P L F Giangrande
Recombinant-activated coagulation factor VIIa (NovoSeven): current development.
May 2007, Vox sanguinis,
A Villar, and S Aronis, and M Morfini, and E Santagostino, and G Auerswald, and H F Thomsen, and E Erhardtsen, and P L F Giangrande
[Application of activated recombinant factor VII (rFVIIa, NovoSeven) in neonatology].
January 2008, Akusherstvo i ginekologiia,
A Villar, and S Aronis, and M Morfini, and E Santagostino, and G Auerswald, and H F Thomsen, and E Erhardtsen, and P L F Giangrande
Small-dose recombinant activated factor VII (NovoSeven) in cardiac surgery.
May 2006, Anesthesia and analgesia,
A Villar, and S Aronis, and M Morfini, and E Santagostino, and G Auerswald, and H F Thomsen, and E Erhardtsen, and P L F Giangrande
A comparison between recombinant activated factor VII (Aryoseven) and Novoseven in patients with congenital factor VII deficiency.
November 2015, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis,
A Villar, and S Aronis, and M Morfini, and E Santagostino, and G Auerswald, and H F Thomsen, and E Erhardtsen, and P L F Giangrande
Newly diagnosed congenital factor VII deficiency and utilization of recombinant activated factor VII (NovoSeven(®)).
January 2013, Clinical pharmacology : advances and applications,
A Villar, and S Aronis, and M Morfini, and E Santagostino, and G Auerswald, and H F Thomsen, and E Erhardtsen, and P L F Giangrande
[Activated recombinant factor VII (Novoseven) in multiple trauma patients: an outcome analysis].
January 2006, Chirurgia (Bucharest, Romania : 1990),
A Villar, and S Aronis, and M Morfini, and E Santagostino, and G Auerswald, and H F Thomsen, and E Erhardtsen, and P L F Giangrande
Pharmacokinetics of recombinant activated factor VII (rFVIIa).
January 2000, Seminars in thrombosis and hemostasis,
Copied contents to your clipboard!